Immune Pharmaceuticals Inc (IMNP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1 BRIDGE PLAZA N, SUITE 270 FORT LEE, NJ 07024 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2018 MRQ | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 6,776 | 271 | 4,543 | 6,767 | 49 | 172 | |||
| Cash and cash equivalents | 6,776 | 271 | 4,543 | 6,767 | 49 | 172 | |||
| Restricted cash and investments | 59 | 31 | 21 | 81 | 909 | ||||
| Other current assets | 255 | 314 | 258 | 99 | 137 | ✕ | |||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 116 | ||
| Total current assets: | 7,031 | 644 | 4,832 | 6,887 | 267 | 1,197 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 316 | 371 | 41 | 47 | 56 | ||||
| Intangible assets, net (including goodwill) | 6,477 | 2,806 | 3,111 | 3,415 | 3,607 | ✕ | |||
| Intangible assets, net (excluding goodwill) | 6,477 | 2,806 | 3,111 | 3,415 | 3,607 | ||||
| Regulated entity, other noncurrent assets | 400 | ||||||||
| Restricted cash and investments | 80 | ||||||||
| Deferred costs | 75 | ||||||||
| Other noncurrent assets | 100 | 339 | 370 | ✕ | |||||
| Other undisclosed noncurrent assets | 15,000 | 14,600 | 27,500 | 27,521 | 27,500 | ||||
| Total noncurrent assets: | 21,577 | 18,461 | 31,352 | 30,977 | 31,234 | 131 | |||
| TOTAL ASSETS: | 28,608 | 19,105 | 36,184 | 37,864 | 31,501 | 1,328 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5,689 | 6,142 | 5,099 | 5,900 | 9,433 | 1,871 | |||
| Taxes payable | 36 | 175 | |||||||
| Employee-related liabilities | 488 | 505 | 465 | ||||||
| Accounts payable | 3,569 | 3,522 | 2,439 | 1,243 | 5,181 | 1,349 | |||
| Accrued liabilities | 2,120 | 2,620 | 2,660 | 4,133 | 3,572 | 57 | |||
| Debt | 3,296 | 2,787 | 1,103 | 2,011 | 6,451 | 12,117 | |||
| Derivative instruments and hedges, liabilities | 84 | ||||||||
| Liability for uncertainty in income taxes | 50 | 40 | |||||||
| Deferred revenue and credits | ✕ | 314 | |||||||
| Due to related parties | 266 | 236 | 30 | 469 | |||||
| Other undisclosed current liabilities | (574) | (5,125) | (6,501) | ||||||
| Total current liabilities: | 9,251 | 9,165 | 6,286 | 7,417 | 11,268 | 7,801 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1,457 | 1,494 | 2,977 | 1,564 | 3,359 | ||||
| Long-term debt, excluding current maturities | 1,457 | 1,442 | 2,886 | 1,564 | 3,359 | ||||
| Capital lease obligations | 52 | 91 | |||||||
| Liabilities, other than long-term debt | 4,142 | 5,933 | 17,399 | 10,870 | 10,870 | 7,496 | |||
| Deferred revenue and credits | ✕ | 7,496 | |||||||
| Deferred tax liabilities, net | 4,142 | 5,933 | 10,870 | 10,870 | 10,870 | ||||
| Derivative instruments and hedges, liabilities | 6,529 | ||||||||
| Other undisclosed noncurrent liabilities | 469 | 521 | |||||||
| Total noncurrent liabilities: | 5,599 | 7,427 | 20,376 | 12,903 | 14,750 | 7,496 | |||
| Total liabilities: | 14,850 | 16,592 | 26,662 | 20,320 | 26,018 | 15,297 | |||
| Temporary equity, carrying amount | 1,659 | ||||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | 13,758 | 2,513 | 7,863 | 17,544 | 5,483 | (13,969) | |||
| Common stock | 2 | 1 | 3 | 2 | 1 | 9 | |||
| Treasury stock, value | (75) | ||||||||
| Additional paid in capital | 127,292 | 98,159 | 70,846 | 62,550 | 27,761 | 236,886 | |||
| Accumulated other comprehensive loss | (1,130) | ||||||||
| Accumulated deficit | (113,536) | (95,647) | (62,986) | (45,829) | (22,279) | (268,811) | |||
| Warrants and rights outstanding | 19,152 | ||||||||
| Other undisclosed equity, attributable to parent | 821 | ||||||||
| Total equity: | 13,758 | 2,513 | 7,863 | 17,544 | 5,483 | (13,969) | |||
| TOTAL LIABILITIES AND EQUITY: | 28,608 | 19,105 | 36,184 | 37,864 | 31,501 | 1,328 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 2 | 19 | 7,804 | |||||
| Revenue, net | ✕ | 7,804 | ||||||
| Cost of revenue | (12,500) | (903) | ||||||
| Cost of goods and services sold | (903) | |||||||
| Gross profit: | (12,500) | 2 | 19 | 6,901 | ||||
| Operating expenses | (12,123) | (14,760) | (15,724) | (16,668) | (9,308) | (8,511) | ||
| Other operating income (expense), net | (7,187) | 3,251 | 1,965 | |||||
| Other expenses | (80) | 43 | 1,965 | |||||
| Other undisclosed operating income (loss) | 7,490 | (2,962) | (961) | |||||
| Operating loss: | (12,123) | (27,260) | (15,724) | (16,363) | (9,000) | (606) | ||
| Nonoperating expense | (28) | (46) | (15) | (3,380) | ||||
| Debt instrument, convertible, beneficial conversion feature | (3,550) | |||||||
| Other nonoperating expense | (28) | (46) | (15) | |||||
| Interest and debt expense | (5,800) | (1,555) | (1,290) | (3,404) | (305) | (1,199) | ||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (1,911) | (8,656) | (128) | (3,783) | 3,556 | 2,614 | ||
| Loss from continuing operations before income taxes: | (19,862) | (37,517) | (17,157) | (23,550) | (5,749) | (2,571) | ||
| Income tax expense (benefit) | 1,973 | 4,856 | (11) | (2) | ||||
| Loss from continuing operations: | (17,889) | (32,661) | (17,157) | (23,550) | (5,760) | (2,573) | ||
| Loss before gain (loss) on sale of properties: | (17,889) | (32,661) | (17,157) | (23,550) | (5,760) | (2,573) | ||
| Net loss attributable to parent: | (17,889) | (32,661) | (17,157) | (23,550) | (5,760) | (2,573) | ||
| Other undisclosed net loss available to common stockholders, basic | (6,864) | (7,973) | (6,959) | (872) | (932) | (3,550) | ||
| Net loss available to common stockholders, basic: | (24,753) | (40,634) | (24,116) | (24,422) | (6,692) | (6,123) | ||
| Convertible preferred dividends | (932) | (3,550) | ||||||
| Net loss available to common stockholders, diluted: | (24,753) | (40,634) | (24,116) | (24,422) | (7,624) | (9,673) | ||
Comprehensive Income ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (17,889) | (32,661) | (17,157) | (23,550) | (5,760) | (2,573) | ||
| Comprehensive loss: | (17,889) | (32,661) | (17,157) | (23,550) | (5,760) | (2,573) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (179) | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (17,889) | (32,661) | (17,157) | (23,550) | (5,760) | (2,752) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.